Patents by Inventor Tove Olafsen

Tove Olafsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10882909
    Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: January 5, 2021
    Assignee: ImaginAb, Inc.
    Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
  • Publication number: 20200140550
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Application
    Filed: January 16, 2020
    Publication date: May 7, 2020
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • Publication number: 20190382488
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Application
    Filed: May 20, 2019
    Publication date: December 19, 2019
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • Publication number: 20190382487
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Application
    Filed: May 20, 2019
    Publication date: December 19, 2019
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • Publication number: 20190309068
    Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
    Type: Application
    Filed: April 25, 2019
    Publication date: October 10, 2019
    Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
  • Publication number: 20190300622
    Abstract: In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided.
    Type: Application
    Filed: February 12, 2019
    Publication date: October 3, 2019
    Inventors: David T. Ho, Tove Olafsen, Arye Lipman
  • Patent number: 10414820
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: September 17, 2019
    Assignee: IMAGINAB, INC.
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • Patent number: 10377826
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: August 13, 2019
    Assignee: IMAGINAB, INC.
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • Patent number: 10301389
    Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 28, 2019
    Assignee: IMAGINAB, INC.
    Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
  • Patent number: 10072080
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: September 11, 2018
    Assignee: ImaginAB, Inc.
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • Publication number: 20180221507
    Abstract: Provided herein are diabodies that comprise extension sequences and antigen binding constructs that comprise extension sequences.
    Type: Application
    Filed: January 10, 2018
    Publication date: August 9, 2018
    Inventors: Jean Marie Gudas, Daulet Kadyl Satpayev, Tove Olafsen, Alessandro Mascioni, Michael Yuri Torgov
  • Publication number: 20180155449
    Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable ? carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
    Type: Application
    Filed: September 18, 2017
    Publication date: June 7, 2018
    Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
  • Patent number: 9765155
    Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: September 19, 2017
    Assignee: City of Hope
    Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
  • Patent number: 9701754
    Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: July 11, 2017
    Assignee: City of Hope
    Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
  • Publication number: 20170051044
    Abstract: Antigen binding constructs that bind to desired targets are disclosed, for example antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.
    Type: Application
    Filed: August 4, 2016
    Publication date: February 23, 2017
    Inventors: Chio Mui Chan, Jean Gudas, Tove Olafsen, Daulet Kadyl Satpayev, Michael Yuri Torgov
  • Publication number: 20170029507
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 2, 2017
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • Publication number: 20160083450
    Abstract: This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided.
    Type: Application
    Filed: February 5, 2015
    Publication date: March 24, 2016
    Inventors: Anna M. WU, Vania E. Kenanova, Tove Olafsen
  • Publication number: 20160024209
    Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 28, 2016
    Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
  • Publication number: 20150191543
    Abstract: Disclosed herein, the parental antibodies from the hybridomas YTS 169.4.2.1 (YTS169) and 2.43 were engineered into minibody and diabody fragments. Both the YTS and 2.43 antibodies bind mCD8+. However, they differ in that the YTS 169 antibodies bind both Lyt2.1 and Lyt2.2 while the 2.43 antibodies bind an epitope that is Lyt2.2 specific. These novel minibodies and diabodies retained their antigen specificity as shown by flow cytometry and ImmunoPET imaging. Most importantly, both the 2.43 and YTS169 minibodies and diabodies produced high contrast ImmunoPET images of CD8+ lymphoid organs at only four hours post-injection.
    Type: Application
    Filed: August 6, 2013
    Publication date: July 9, 2015
    Inventors: Anna M. Wu, Richard Tavaré, Tove Olafsen
  • Publication number: 20150118252
    Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
    Type: Application
    Filed: June 13, 2013
    Publication date: April 30, 2015
    Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch